Seeking Alpha
07 Oct 2026, 13:50 UTC · 1h ago
Xencor: Better Funding For Obexelimab
Impact · against what's priced in
The settlement with Alexion and the pending PDUFA date for obexelimab are positive developments for Xencor, but they primarily serve to stabilize the financial runway rather than create a new growth catalyst. The net impact is mildly positive as it reduces immediate insolvency risk leading up to the FDA decision.
- XNCR+0.40
No priced-in read yet
- In context
The $105 million settlement with Alexion provides a critical cash infusion that ensures the company has enough runway to reach the obexelimab PDUFA decision for IgG4-related disease.
Read from the article alone
Search tags
